GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Intra Cellular Therapies
Iteris provides technology solutions for smart mobility, including sensors and traffic management software, and agriculture. Its stock price reflects the demand for data and analytics to improve efficiency in these two major industries.
Share prices of companies in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders such as schizophrenia and depression. We've categorized it under the Neuroscience category. The chart below reflects how investors assess the risks in this complex area.
Broad Market Index - GURU.Markets
Intra-Cellular Therapies is a biotech company that has developed and commercialized drugs for the treatment of schizophrenia and bipolar disorder. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with the ITCI.
Change in the price of a company, segment, and market as a whole per day
ITCI - Daily change in the company's share price Intra Cellular Therapies
Intra-Cellular Therapies' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to sales of its psychiatric drug products and new research data.
Daily change in the price of a set of shares in a market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of neuropsychiatric disorders. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Intra-Cellular Therapies is a biotech company specializing in the treatment of central nervous system diseases. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Intra Cellular Therapies
Intra-Cellular Therapies' year-over-year performance is a success story for its drug, Caplyta. Its market capitalization growth over the past 12 months is directly linked to increased sales of this unique drug for the treatment of schizophrenia and bipolar depression. Its valuation is a bet on Caplyta becoming a blockbuster in the vast mental health market.
Annual dynamics of market capitalization of the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on treating CNS diseases. Its success depends on the commercialization of its key drugs. The graph shows how its scientific achievements, competitive environment, and R&D potential influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intra-Cellular Therapies, a biopharmaceutical company with approved drugs for schizophrenia and bipolar disorder, is a commercial success story. Its year-over-year market capitalization reflects sales growth and potential for expanded indications, which could allow it to outperform the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Intra Cellular Therapies
Intra-Cellular is a commercial biopharmaceutical company. Its monthly growth is primarily driven by sales growth of its key drug, Caplyta. Quarterly revenue reports and indication expansion news are the main drivers.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector, particularly in psychiatry. For Intra-Cellular, a commercial-stage company, it's the backdrop. Its movements show how the successful launch and sales growth of its key drug, Caplyta, are allowing it to outperform a volatile sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intra-Cellular Therapies is a biopharmaceutical company that successfully launched a drug for the treatment of schizophrenia and bipolar disorder. A full-market chart allows you to assess how ITCI shares are performing after transitioning from risky development to commercial growth, and the extent to which its product allows it to defy overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company. Its weekly stock price is driven by sales reports for its approved drug for schizophrenia and bipolar disorder, as well as news about clinical trials.
Weekly dynamics of market capitalization of the market segment - Neuro
Intra-Cellular Therapies develops drugs to treat severe mental disorders such as schizophrenia and bipolar disorder. This is a socially significant but highly complex market. The chart below shows how investors view the commercial potential of its drugs and clinical data compared to other companies in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Intra-Cellular Therapies has achieved success with its drug Caplyta. Now its stock performance depends entirely on quarterly sales reports and the company's ability to exceed analyst expectations. Investors are also monitoring news about indication expansion. The chart will show how these internal drivers are driving the stock.
Market capitalization of the company, segment and market as a whole
ITCI - Market capitalization of the company Intra Cellular Therapies
Intra-Cellular Therapies' market capitalization chart is a biotech success story. Its impressive growth is based on the commercial success of its drug Caplyta for the treatment of schizophrenia and bipolar disorder. Investors are praising its potential to become a blockbuster in the vast mental health market.
ITCI - Share of the company's market capitalization Intra Cellular Therapies within the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company that has achieved success with a drug for the treatment of schizophrenia and bipolar disorder. Its market share in the psychiatric drug sector is significant and growing. The market capitalization chart reflects the commercial success of its key product and the potential of its other developments.
Market capitalization of the market segment - Neuro
The chart below shows the total value of the neurological pharmaceutical sector. Intra-Cellular Therapies is one of the most successful stories in this field. The company developed and commercialized an innovative drug for the treatment of schizophrenia and bipolar disorder. Its market success exemplifies how a scientific breakthrough can create a multi-billion-dollar company.
Market capitalization of all companies included in a broad market index - GURU.Markets
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders such as schizophrenia and depression. Its market capitalization reflects its success. The chart below shows the weightings of companies working in this field.
Book value capitalization of the company, segment and market as a whole
ITCI - Book value capitalization of the company Intra Cellular Therapies
Intra-Cellular's book value is derived from its intellectual property and its commercial drug, Caplyta, for the treatment of schizophrenia and bipolar disorder. The graph is a story of successful commercialization, where revenue from one product forms a solid financial foundation for its further promotion and new research.
ITCI - Share of the company's book capitalization Intra Cellular Therapies within the market segment - Neuro
Intra-Cellular Therapies develops drugs for the treatment of central nervous system disorders. The chart shows its share of commercial and R&D assets. This includes its sales and marketing infrastructure, as well as laboratories where new mechanisms of brain function are explored.
Market segment balance sheet capitalization - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. Their value lies in their patents and clinical trial results. A book value chart will show their R&D base but won't reflect the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Intra-Cellular Therapies' resource base consists of R&D centers and laboratories where their drugs for the treatment of schizophrenia and bipolar disorder were developed. The chart shows how the company's scientific and physical capital has grown.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on diseases of the central nervous system. It already has an approved drug. The chart shows how the market values current sales and the potential of other drugs in development. This is an estimate of future cash flows, not just current assets.
Market to book capitalization ratio in a market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company whose lead drug, Caplyta, is designed to treat schizophrenia and bipolar disorder. Its value lies in the drug's commercial success. The chart shows how the market values its current and future sales, relating them to the company's assets.
Market to book capitalization ratio for the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company with an approved drug for the treatment of psychiatric disorders. Its valuation reflects both current sales and the potential for new indications. This chart shows a high premium to book value, driven by commercial success and strong intellectual property.
Debts of the company, segment and market as a whole
ITCI - Company debts Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company that successfully launched a drug for the treatment of schizophrenia and bipolar disorder. This chart shows its progression to the commercial stage. Revenues from sales now fund further research to expand indications and develop new drugs.
Market segment debts - Neuro
Intra-Cellular Therapies is a biopharmaceutical company that achieved success with a drug for the treatment of schizophrenia and bipolar disorder. Now, its goal is to maximize sales and expand the use of its drug. This chart shows how the company's financial strategy is changing as it transitions from development to commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company with an approved drug for the treatment of psychiatric disorders. This chart shows its financial structure. Having a commercial product allows it to use moderate debt to fund marketing and R&D.
Market segment debt to market segment book capitalization - Neuro
Intra-Cellular Therapies is a biopharmaceutical company specializing in the treatment of central nervous system diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance the commercialization of its approved drugs and further research.
Debt to book value of all companies in the market
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. It already has an approved drug, but R&D is ongoing. This graph of total market debt helps assess how the company balances sales revenue with investment in new development, and how it finances this process.
P/E of the company, segment and market as a whole
P/E - Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system (CNS) disorders. This chart reflects investor valuations of its key drug, Caplyta, for the treatment of schizophrenia and bipolar disorder. The valuation is driven by sales volume and success in expanding its use.
P/E of the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its flagship product, Caplyta, is approved for the treatment of schizophrenia and bipolar disorder. This chart shows the average valuation for the neuroscience sector, reflecting how investors value companies with successful commercial products in this complex field.
P/E of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. Its valuation depends on the commercial success of its approved drugs and the results of new drug candidates. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the central nervous system market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, such as schizophrenia and bipolar disorder. This chart reflects expected future revenue from sales of its lead drug and the potential of its other developments.
%20P%2FE%20Intra%20Cellular%20Therapies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Intra-Cellular-Therapies&v=1772628789029 "Chart of the company's future (projected) P/E Intra Cellular Therapies")
Future (projected) P/E of the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Their lead product is designed to treat schizophrenia and bipolar disorder. The chart reflects average expectations for the biotech sector. ITCI's position relative to this benchmark reflects the market's assessment of the commercial success of their flagship drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772628789076 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its key product, Caplyta, is approved for the treatment of schizophrenia and bipolar disorder. This chart of overall market expectations provides a framework for evaluating pharmaceutical companies with commercialized products in large and complex markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628789136 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its financial performance, as shown in the graph, depends on sales of its drug Caplyta for the treatment of schizophrenia and bipolar disorder.
Profit of companies in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as schizophrenia and bipolar disorder. This chart shows the total revenue in its sector, illustrating the level of investor confidence in the commercial potential of its developments to treat complex neurological and psychiatric conditions.
Overall market profit
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its commercial success depends on sales of already approved drugs and the results of new studies. Demand for mental health medications is largely independent of economic cycles, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system disorders. Its flagship product is approved for the treatment of schizophrenia and bipolar disorder. This chart shows analysts' expectations for sales growth for this drug and progress in the development of other candidates.
%20profit%20of%20the%20company%20Intra%20Cellular%20Therapies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Intra-Cellular-Therapies&v=1772628789249 "Graph of future (projected) profit of the company Intra Cellular Therapies")
Future (predicted) profit of companies in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as schizophrenia and bipolar disorder. This chart shows forecasts for the entire pharmaceutical sector, helping to assess the company's progress in addressing complex challenges in psychiatry and neurology, where the need for new drugs is extremely high.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772628789259 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. Its success depends on sales of its approved drugs and the results of new research. General economic cycles, reflected in this chart, have only an indirect impact on its business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628789275 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company with an approved drug for the treatment of schizophrenia and bipolar disorder. This chart shows how the market perceives the drug's commercial success and its potential for expanded indications. These trends are a barometer of its sales and competitive position.
P/S market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Revenue is generated from sales of its lead drug for the treatment of schizophrenia. This neuroscience chart helps assess the commercial success of its current product and the potential for future developments.
P/S of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its main commercial product is used to treat schizophrenia and bipolar disorder. This market revenue valuation chart helps understand how investors value a company with a successful product in the complex field of psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its lead product is designed to treat schizophrenia and bipolar disorder. This chart shows how the market estimates future sales of this important mental health drug.
%20P%2FS%20Intra%20Cellular%20Therapies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Intra-Cellular-Therapies&v=1772628789382 "The graph of the company's future (projected) P/S Intra Cellular Therapies")
Future (projected) P/S of the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company whose drug Caplyta is approved for the treatment of schizophrenia and bipolar disorder. The company's high valuation reflects investor expectations that Caplyta will become a blockbuster in the vast mental health market thanks to its favorable side-effect profile.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772628789425 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on the treatment of central nervous system disorders. Its success depends on the commercialization of its key drugs. In the overall revenue expectations pictured in the chart, ITCI represents a large and important segment of the pharmaceutical market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628789449 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company. This chart shows revenue from sales of its lead product, Caplyta, which is approved for the treatment of schizophrenia and bipolar depression. A successful commercial launch and acceptance by psychiatrists are key growth drivers.
Sales of companies in the market segment - Neuro
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on treating diseases of the central nervous system. Its flagship product, Caplyta, is approved for the treatment of schizophrenia and bipolar depression. This chart shows revenue in the neuroscience segment of the company. ITCI is a successful commercial player in the vast mental health market.
Overall market sales
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. Its commercial success depends on sales of its lead drug. This pattern of overall economic activity impacts the healthcare system. A stable economy ensures better insurance coverage and effective demand for innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its primary revenue comes from Caplyta, a drug for the treatment of schizophrenia and bipolar disorder. This chart reflects analyst sales forecasts, which assess the drug's commercial success and potential for increased adoption.
%20sales%20of%20the%20company%20Intra%20Cellular%20Therapies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Intra-Cellular-Therapies&v=1772628789612 "Schedule of future (projected) sales of the company Intra Cellular Therapies")
Future (projected) sales of companies in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. This chart details projected sales of their lead drug for schizophrenia and bipolar disorder. This allows analysts to assess the market potential of this key product.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772628789727 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company that has developed and markets an innovative drug for the treatment of schizophrenia and bipolar disorder. Its commercial success depends on the drug's acceptance by doctors and patients. This graph shows overall healthcare costs, and the company's sales are an indicator of demand for new, safer antipsychotics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628789807 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company that has developed and commercialized drugs for the treatment of schizophrenia and bipolar disorder. Its profitability is directly dependent on sales of these drugs. The chart shows how the company translates its scientific advances in psychiatry into significant financial returns.
Market segment marginality - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its key product, Caplyta, is approved for the treatment of schizophrenia and bipolar depression. This chart shows the company's profitability. Success depends on Caplyta's sales volume and its acceptance by physicians.
Market marginality as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on treating diseases of the central nervous system. Its commercial success depends on physician acceptance of its drugs and insurance coverage. This gross profitability chart reflects the financial health of the healthcare system, which influences the willingness to pay for innovative drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company that successfully developed and commercialized a drug for the treatment of schizophrenia and bipolar disorder. This chart shows the team's journey from research to the creation of a commercial structure to bring their blockbuster to market.
Share of the company's employees Intra Cellular Therapies within the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company that has successfully launched drugs for the treatment of schizophrenia and bipolar disorder. As a commercial company, its staff includes a large sales team. This chart reflects its full operational scope: from ongoing research to marketing and promoting its drugs to physicians.
Number of employees in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on diseases of the central nervous system. This chart, showing employment in the neuroscience sector, illustrates the enormous need for new treatments for mental disorders. For Intra-Cellular, with its successful drug, growth in this area means market expansion and further research.
Number of employees in the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system disorders such as schizophrenia and depression. Demand for its drugs depends on their inclusion in insurance plans. The growth in overall employment, shown in this chart, supports the health insurance system, ensuring patient access to new and effective treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Intra Cellular Therapies (ITCI)
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on CNS disorders (e.g., schizophrenia). They already have an approved drug. This metric reflects both the value of their current sales (which require staff) and the potential of their R&D pipeline (IP). It's a balance between commercial structure and intellectual capital.
%20of%20the%20company%20Intra%20Cellular%20Therapies%20(ITCI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Intra-Cellular-Therapies-ITCI&v=1772628790181 "Chart of market capitalization per employee (in thousands of dollars) of the company Intra Cellular Therapies (ITCI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company that has successfully launched a drug for the treatment of schizophrenia and bipolar disorder. This metric reflects both the current revenue from sales of this drug and the potential of other developments in its pipeline.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772628790209 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Intra-Cellular Therapies is a biopharmaceutical company whose drug Caplyta is approved for the treatment of schizophrenia and bipolar disorder. Having a successful product on the market is key. This chart for Intra-Cellular shows how the commercialization of a single blockbuster can lead to colossal market value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628790267 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Intra Cellular Therapies (ITCI)
Intra-Cellular Therapies is a biotech success story. They have an approved and commercially successful drug (Caplyta) for treating psychiatric disorders. This graph demonstrates the enormous profitability that a single patented "blockbuster" can generate. A small team generates enormous revenue from intellectual property.
%20Chart%20Intra%20Cellular%20Therapies%20(ITCI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Intra-Cellular-Therapies-ITCI&v=1772628790347 "Company Profit Per Employee (in thousands of dollars) Chart Intra Cellular Therapies (ITCI)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system disorders, such as schizophrenia and bipolar disorder. In neuroscience, clinical trial effectiveness determines success. This chart reflects the value each employee creates on the path to commercialization of life-saving therapies.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772628790410 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system disorders. Their key drug, Caplyta, is approved for the treatment of schizophrenia and bipolar disorder. This chart measures the average profit per employee across the economy. It provides investors with context: how effective a pharmaceutical business, where one successful drug recoups R&D costs, is in terms of employee productivity.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628790456 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Intra Cellular Therapies (ITCI)
Intra-Cellular Therapies is a biopharmaceutical company whose revenue is generated by sales of its drug Caplyta for the treatment of schizophrenia and bipolar disorder. Revenue per employee reflects the commercial success of this key product. The chart shows how the company is growing sales by promoting its drug to psychiatrists and patients.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Intra-Cellular-Therapies-ITCI&v=1772628790535 "Sales chart per company employee Intra Cellular Therapies (ITCI)")
Sales per employee in the market segment - Neuro
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on treating CNS disorders, known for its drug Caplyta (for schizophrenia and bipolar disorder). This chart shows the average revenue per employee in the segment. It helps assess how effectively ITCI is using its sales team to commercialize Caplyta.
Sales per employee for the market as a whole
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company that already has the approved blockbuster drug Caplyta for the treatment of schizophrenia and bipolar depression. This metric demonstrates their phenomenal commercial success, demonstrating the enormous revenue generated by their team (R&D, marketing, and sales) from the sale of a single drug.
Short shares by company, segment and market as a whole
Shares shorted by company Intra Cellular Therapies (ITCI)
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company whose success depends on sales of a single drug, Caplyta, approved for the treatment of schizophrenia and bipolar disorder. This chart shows short interest. The high bearish bets reflect concerns about the highly competitive antipsychotic market and the risks associated with dependence on a single product. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Intra-Cellular-Therapies-ITCI&v=1772628790728 "Short Shares Chart for the Company Intra Cellular Therapies (ITCI)")
Shares shorted by market segment - Neuro
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on treating CNS disorders. Their flagship drug is Caplyta (for schizophrenia and bipolar disorder). The chart below shows the overall short position in the CNS biotech sector. It shows the investor confidence in the commercial success of these drugs.
Shares shorted by the overall market
Intra-Cellular Therapies (ITCI) has successfully launched drugs for schizophrenia and depression, but is still in the aggressive R&D and marketing phase. This chart measures overall fear. When investors are fearful, they doubt the speed of commercialization. They worry that a recession will slow the launch of new expensive drugs and continue to burn through cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Intra Cellular Therapies (ITCI)
Intra-Cellular Therapies is a "one-drug story." Their success is built on Caplyta, a drug for schizophrenia and bipolar depression. This indicator measures the "temperature" of Caplyta's market acceptance. It "heats up" every time quarterly sales exceed Wall Street's wildest expectations.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Intra-Cellular-Therapies-ITCI&v=1772628790918 "RSI 14 indicator chart for the company's stock Intra Cellular Therapies (ITCI)")
RSI 14 Market Segment - Neuro
Intra-Cellular Therapies is a biopharmaceutical company whose flagship drug, Caplyta, is approved for the treatment of schizophrenia and bipolar depression. It is a major player in the complex psychiatry niche. This chart shows the overall momentum in the neurobiological segment. It helps distinguish the reaction to Caplyta sales from the general euphoria or panic felt across this complex industry.
RSI 14 for the overall market
Intra-Cellular (ITCI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ITCI (Intra Cellular Therapies)
Intra-Cellular Therapies (ITCI) is a biopharmaceutical company whose key product, Caplyta, is approved for the treatment of schizophrenia and bipolar depression. This chart shows the average 12-month price target from analysts, based on their forecasts for Caplyta's prescription growth (sales).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ITCI-Intra-Cellular-Therapies&v=1772628791046 "A chart showing analyst consensus forecasts for the expected stock price. ITCI (Intra Cellular Therapies)")
The difference between the consensus estimate and the actual stock price ITCI (Intra Cellular Therapies)
Intra-Cellular (ITCI) is a biopharmaceutical unicorn. Their drug Caplyta, already approved for schizophrenia and depression, has the potential to become a mega-blockbuster. This chart shows the difference between the market valuation and the consensus estimate. It highlights the enormous commercial potential analysts are placing on this single drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ITCI-Intra-Cellular-Therapies&v=1772628791097 "A chart showing the difference between the consensus forecast and the actual stock price. ITCI (Intra Cellular Therapies)")
Analyst consensus forecast for stock prices by market segment - Neuro
Intra-Cellular (ITCI) is a commercial biotech company focused on complex brain disorders. Its flagship drug, Caplyta, is approved for the treatment of schizophrenia and bipolar depression. This chart reflects the collective opinion of the entire neuroscience/CNS pharmaceutical sector. It shows whether experts believe in the commercial success of new psychiatric drugs.
Analysts' consensus forecast for the overall market share price
Intra-Cellular Therapies is a biopharmaceutical company focused on treating central nervous system disorders (schizophrenia, depression). Their drug Caplyta is driving growth. This chart shows overall market sentiment. For ITCI, which operates in the "defensive" sector (healthcare), overall optimism (the rising chart) is important to support its high valuation, although demand for their drug is stable.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Intra Cellular Therapies
Intra-Cellular (ITCI) is an R&D company that went commercial. Their first (and major) blockbuster, Caplyta, is an FDA-approved atypical antipsychotic (pill) for the treatment of schizophrenia and bipolar depression. This chart summarizes their commercialization history. It reflects the rapid sales growth (ramp-up) of Caplyta and their high R&D potential.
AKIMA Market Segment Index - Neuro
Intra-Cellular Therapies is a biopharmaceutical company focused on neurological diseases. Their flagship drug, Caplyta, is approved for the treatment of schizophrenia and bipolar disorder. This chart compares their composite index to the sector, showing how their brain pharma outperforms its competitors.
The AKIM Index for the overall market
Intra-Cellular Therapies is a biopharmaceutical company known for its drug Caplyta for the treatment of bipolar disorder and schizophrenia. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this successful commercial story in the central nervous system compares to overall economic trends.
